- Home
- PHAR vs REPL Comparison
PHAR vs REPL Comparison
Compare PHAR & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- REPL
- Stock Information
- Founded
- PHAR 1988
- REPL 2015
- Country
- PHAR Netherlands
- REPL United States
- Employees
- PHAR N/A
- REPL N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- REPL Health Care
- Exchange
- PHAR Nasdaq
- REPL Nasdaq
- Market Cap
- PHAR 587.5M
- REPL 578.4M
- IPO Year
- PHAR N/A
- REPL 2018
- Fundamental
- Price
- PHAR $10.03
- REPL $7.71
- Analyst Decision
- PHAR Strong Buy
- REPL Strong Buy
- Analyst Count
- PHAR 3
- REPL 6
- Target Price
- PHAR $30.00
- REPL $20.00
- AVG Volume (30 Days)
- PHAR 3.0K
- REPL 1.1M
- Earning Date
- PHAR 05-08-2025
- REPL 05-19-2025
- Dividend Yield
- PHAR N/A
- REPL N/A
- EPS Growth
- PHAR N/A
- REPL N/A
- EPS
- PHAR N/A
- REPL N/A
- Revenue
- PHAR $320,708,000.00
- REPL N/A
- Revenue This Year
- PHAR $12.39
- REPL $31.16
- Revenue Next Year
- PHAR $9.84
- REPL N/A
- P/E Ratio
- PHAR N/A
- REPL N/A
- Revenue Growth
- PHAR 24.13
- REPL N/A
- 52 Week Low
- PHAR $6.65
- REPL $4.92
- 52 Week High
- PHAR $11.07
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- PHAR 71.76
- REPL 39.21
- Support Level
- PHAR $8.60
- REPL $6.93
- Resistance Level
- PHAR $10.28
- REPL $10.30
- Average True Range (ATR)
- PHAR 0.30
- REPL 0.73
- MACD
- PHAR 0.17
- REPL -0.07
- Stochastic Oscillator
- PHAR 88.79
- REPL 23.15
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.